Vise Technologies Inc. Purchases 862 Shares of Novo Nordisk A/S (NYSE:NVO)

Vise Technologies Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,443 shares of the company’s stock after buying an additional 862 shares during the quarter. Vise Technologies Inc.’s holdings in Novo Nordisk A/S were worth $1,759,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gordian Capital Singapore Pte Ltd boosted its position in Novo Nordisk A/S by 85.8% during the fourth quarter. Gordian Capital Singapore Pte Ltd now owns 6,500 shares of the company’s stock worth $557,000 after purchasing an additional 3,002 shares during the period. Inspire Trust Co. N.A. bought a new position in Novo Nordisk A/S during the fourth quarter worth $1,892,000. Mosaic Family Wealth Partners LLC boosted its position in Novo Nordisk A/S by 31.5% during the fourth quarter. Mosaic Family Wealth Partners LLC now owns 2,941 shares of the company’s stock worth $253,000 after purchasing an additional 704 shares during the period. Pinkerton Retirement Specialists LLC boosted its position in Novo Nordisk A/S by 1.3% during the fourth quarter. Pinkerton Retirement Specialists LLC now owns 25,247 shares of the company’s stock worth $2,172,000 after purchasing an additional 317 shares during the period. Finally, Harmony Asset Management LLC boosted its position in Novo Nordisk A/S by 1.6% during the fourth quarter. Harmony Asset Management LLC now owns 61,777 shares of the company’s stock worth $5,314,000 after purchasing an additional 950 shares during the period. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $135.00.

Novo Nordisk A/S Stock Down 1.3%

NVO stock opened at $67.26 on Friday. The company has a market cap of $301.83 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The business has a 50-day simple moving average of $66.31 and a 200 day simple moving average of $83.07. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.